St. Jude Medical Angio-Seal VIP Vascular Closure Device

Not Applicable

Completed

• Conditions: Patients Requiring a Diagnostic and/or Interventional Diagnostic Procedure
• Interventions: Device: Angio-Seal VIP

• Registration Number: NCT01393041
• Lead Sponsor: Abbott Medical Devices

Brief Summary

The purpose of this clinical study is to assess device deployment characteristics and performance, as well as adverse events (vascular complications) of the SJM Angio-Seal VIP 6 French device utilizing the SJM collagen.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-06
• Study First Submitted: 2011-06-22
• Primary Completion: 2011-07
• Study First Submitted QC: 2011-07-11
• Study First Posted: 2011-07-13
• Study Completion: 2011-12
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-01
• Last Update Posted: 2019-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Patient is undergoing a diagnostic and/or interventional endovascular procedure via a retrograde femoral arterial access.
2. Patient is of legal age.
3. Patient has given written informed consent for participation prior to the procedure.
4. Patient is willing to undergo all study procedures and adhere to data collection and follow-up requirements.

Exclusion Criteria

1. Patient is unable to provide written informed consent.
2. Patient has an inability or is unwilling to adhere to data collection and follow-up requirements.
3. Patients who are pregnant or lactating.
4. Patient may not participate in another clinical trial which has the potential to impact hemostasis (pharmaceutical/ device/ homeopathic).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Angio-Seal VIP	Angio-Seal VIP	-

Primary Outcome Measures

Name	Time	Method
Device deployment characteristics and performance	At procedure	Device Deployment Success and rationale for non-deployment, procedural circumstances present during deployment such as type of procedure and procedure duration, Time to hemostasis, and assessment of vascular complications prior to leaving the cath lab. Data will be summarized using descriptive statistics in addition to listings or summary data tables being provided.
Adverse events (vascular complications)	Ongoing	Adverse events (vascular complications) out to 30 days post-procedure on patients who have undegone a diagnostic and/or interventional procedure.

Secondary Outcome Measures

Name	Time	Method
Time to hemostasis	The time elapsed from device deployment (cutting of the suture) to complete cessation of arterial bleeding, stratified as hemostasis in less than 1 minute, 1-5 minutes, or greater than 5 minutes.
Rate of minor vascular complications	Ongoing

Trial Locations

Locations (1)

Klinikum Luedenscheid; 🇩🇪 Luedenscheid, Germany